Message #24 From:
Stock News Bot Date: November 6, 2006 04:00:00 AM
CEMI News Chembio Receives Order for 990,000 SURE CHECK(R) HIV 1/2 Rapid Tests From Distributor in Mexico
MEDFORD, N.Y.--(BUSINESS WIRE)--Chembio Diagnostics, Inc. (OTCBB:CEMI) has received a purchase order for
990,000 of its SURE CHECK®HIV 1/2 rapid tests
from the Company’s exclusive distributor in
Mexico. The tests will be used for the Mexican Ministry of Health
program to screen pregnant women. During the next several weeks, a
shipment schedule will be finalized with the distributor.
Avi Pelossof, Vice President of Sales Marketing and Business Development
of Chembio, commented, "We are pleased that SURE CHECK®HIV 1/2 was selected by the Mexican Ministry of Health for what we
believe to be the largest scale implementation of rapid HIV tests in
that country. This order also underscores the progress we are making in
the Latin American market with our products: During the last year we
have grown our business in that region through our agreement with
Bio-Manguinhos (an affiliate of the Brazilian Ministry of Health), the
national Chagas screening program in Bolivia (using our Chagas STAT-PAK™),
and now this important program in Mexico. We believe this international
business can provide us with continued growth as we enter the U.S. HIV
rapid test market through the agreement we recently announced with our
strategic partner, Inverness Medical Innovations, Inc. (AMEX: IMA).”
The Mexican Ministry of Health program is designed to screen pregnant
women throughout Mexico in an attempt to prevent transmission of the HIV
virus to children. As part of the program, women who test positive for
HIV can receive counseling, and they and their newborns can also be put
on treatment and receive antiretroviral drugs.
ABOUT CHEMBIO
Chembio Diagnostics, Inc., a developer and manufacturer of rapid
diagnostic tests for infectious diseases, is on the frontlines of the
global battle against the AIDS pandemic. The Company has received
marketing approval from the FDA for its SURE CHECK®HIV 1/2 and HIV 1/2 STAT-PAK™ rapid tests. The
Company also manufactures rapid tests for veterinary Tuberculosis and
Chagas Disease, and has developed a patent-pending technology, the Dual
Path Platform (DPP™), for its next generation
HIV and other rapid tests. For additional information please visit www.chembio.com.
FORWARD-LOOKING STATEMENTS
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of
1933, as amended. Forward-looking statements include statements
regarding the intent, belief or current expectations of the Company and
its management.Such statements are estimates only, as the
Company has not completed the preparation of its financial statements
for those periods, nor has its auditor completed the audit of those
results. Actual revenue may differ materially from those anticipated in
this press release. Such statements reflect management's current views,
are based on certain assumptions and involve risks and uncertainties.
Actual results, events, or performance may differ materially from the
above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not
limited to Chembio's ability to obtain additional financing, to obtain
regulatory approvals in a timely manner, and the demand for Chembio's
products. Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur
after the date hereof or to reflect any change in Chembio's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events. Factors that may impact Chembio's success are more
fully disclosed in Chembio's most recent public filings with the U.S.
Securities and Exchange Commission.
